A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Clinical trial NCT03605849 · COMPLETED

Trial details

NCT number: NCT03605849
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Attention Deficit Disorder Attention Deficit Hyperactivity Disorder

Start date: 2019-02-14
Primary completion: 2021-09-07
Enrollment: 662

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.